Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1999 Mar-Apr;5(2):224–234. doi: 10.3201/eid0502.990206

Bacterial toxins: friends or foes?

C K Schmitt 1, K C Meysick 1, A D O'Brien 1
PMCID: PMC2640701  PMID: 10221874

Abstract

Many emerging and reemerging bacterial pathogens synthesize toxins that serve as primary virulence factors. We highlight seven bacterial toxins produced by well-established or newly emergent pathogenic microbes. These toxins, which affect eukaryotic cells by a variety of means, include Staphylococcus aureus alpha-toxin, Shiga toxin, cytotoxic necrotizing factor type 1, Escherichia coli heat-stable toxin, botulinum and tetanus neurotoxins, and S. aureus toxic-shock syndrome toxin. For each, we discuss the information available on its synthesis and structure, mode of action, and contribution to virulence. We also review the role certain toxins have played in unraveling signal pathways in eukaryotic cells and summarize the beneficial uses of toxins and toxoids. Our intent is to illustrate the importance of the analysis of bacterial toxins to both basic and applied sciences.

Full Text

The Full Text of this article is available as a PDF (716.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreu A., Stapleton A. E., Fennell C., Lockman H. A., Xercavins M., Fernandez F., Stamm W. E. Urovirulence determinants in Escherichia coli strains causing prostatitis. J Infect Dis. 1997 Aug;176(2):464–469. doi: 10.1086/514065. [DOI] [PubMed] [Google Scholar]
  2. Bhakdi S., Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev. 1991 Dec;55(4):733–751. doi: 10.1128/mr.55.4.733-751.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bohach G. A., Stauffacher C. V., Ohlendorf D. H., Chi Y. I., Vath G. M., Schlievert P. M. The staphylococcal and streptococcal pyrogenic toxin family. Adv Exp Med Biol. 1996;391:131–154. doi: 10.1007/978-1-4613-0361-9_8. [DOI] [PubMed] [Google Scholar]
  4. Carter S. R., Seiff S. R. Cosmetic botulinum toxin injections. Int Ophthalmol Clin. 1997 Summer;37(3):69–79. doi: 10.1097/00004397-199703730-00006. [DOI] [PubMed] [Google Scholar]
  5. Centers for Disease Control (CDC) Isolation of E. coli O157:H7 from sporadic cases of hemorrhagic colitis - United States. MMWR Morb Mortal Wkly Rep. 1982 Nov 5;31(43):580–585. [PubMed] [Google Scholar]
  6. De Rycke J., González E. A., Blanco J., Oswald E., Blanco M., Boivin R. Evidence for two types of cytotoxic necrotizing factor in human and animal clinical isolates of Escherichia coli. J Clin Microbiol. 1990 Apr;28(4):694–699. doi: 10.1128/jcm.28.4.694-699.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988 Jan 15;171(1-2):45–50. doi: 10.1111/j.1432-1033.1988.tb13756.x. [DOI] [PubMed] [Google Scholar]
  8. Falbo V., Pace T., Picci L., Pizzi E., Caprioli A. Isolation and nucleotide sequence of the gene encoding cytotoxic necrotizing factor 1 of Escherichia coli. Infect Immun. 1993 Nov;61(11):4909–4914. doi: 10.1128/iai.61.11.4909-4914.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flatau G., Lemichez E., Gauthier M., Chardin P., Paris S., Fiorentini C., Boquet P. Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. Nature. 1997 Jun 12;387(6634):729–733. doi: 10.1038/42743. [DOI] [PubMed] [Google Scholar]
  10. Ghetie M. A., Ghetie V., Vitetta E. S. Immunotoxins for the treatment of B-cell lymphomas. Mol Med. 1997 Jul;3(7):420–427. [PMC free article] [PubMed] [Google Scholar]
  11. Halpern J. L., Neale E. A. Neurospecific binding, internalization, and retrograde axonal transport. Curr Top Microbiol Immunol. 1995;195:221–241. doi: 10.1007/978-3-642-85173-5_10. [DOI] [PubMed] [Google Scholar]
  12. Harrington D. J. Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Infect Immun. 1996 Jun;64(6):1885–1891. doi: 10.1128/iai.64.6.1885-1891.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 1993 Sep;11(12):1179–1184. doi: 10.1016/0264-410x(93)90039-z. [DOI] [PubMed] [Google Scholar]
  14. Horiguchi Y., Inoue N., Masuda M., Kashimoto T., Katahira J., Sugimoto N., Matsuda M. Bordetella bronchiseptica dermonecrotizing toxin induces reorganization of actin stress fibers through deamidation of Gln-63 of the GTP-binding protein Rho. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11623–11626. doi: 10.1073/pnas.94.21.11623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jahn R., Hanson P. I., Otto H., Ahnert-Hilger G. Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion. Cold Spring Harb Symp Quant Biol. 1995;60:329–335. doi: 10.1101/sqb.1995.060.01.037. [DOI] [PubMed] [Google Scholar]
  16. Kessler K. R., Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicology. 1997;18(3):761–770. [PubMed] [Google Scholar]
  17. Lemichez E., Flatau G., Bruzzone M., Boquet P., Gauthier M. Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Mol Microbiol. 1997 Jun;24(5):1061–1070. doi: 10.1046/j.1365-2958.1997.4151781.x. [DOI] [PubMed] [Google Scholar]
  18. Lesieur C., Vécsey-Semjén B., Abrami L., Fivaz M., Gisou van der Goot F. Membrane insertion: The strategies of toxins (review). Mol Membr Biol. 1997 Apr-Jun;14(2):45–64. doi: 10.3109/09687689709068435. [DOI] [PubMed] [Google Scholar]
  19. Levine S. R. Thrombolytic therapy for stroke: the new paradigm. Hosp Pract (1995) 1997 Nov 15;32(11):57-64, 69-73. doi: 10.1080/21548331.1997.11443597. [DOI] [PubMed] [Google Scholar]
  20. Lottenberg R., Minning-Wenz D., Boyle M. D. Capturing host plasmin(ogen): a common mechanism for invasive pathogens? Trends Microbiol. 1994 Jan;2(1):20–24. doi: 10.1016/0966-842x(94)90340-9. [DOI] [PubMed] [Google Scholar]
  21. Maseri A., Andreotti F. Targeting new thrombolytic regimens at specific patient groups: implications for research and cost-containment. Eur Heart J. 1997 Dec;18 (Suppl F):F28–F35. doi: 10.1093/eurheartj/18.suppl_f.28. [DOI] [PubMed] [Google Scholar]
  22. Melton-Celsa A. R., Darnell S. C., O'Brien A. D. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun. 1996 May;64(5):1569–1576. doi: 10.1128/iai.64.5.1569-1576.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. O'Brien A. O., Lively T. A., Chen M. E., Rothman S. W., Formal S. B. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet. 1983 Mar 26;1(8326 Pt 1):702–702. doi: 10.1016/s0140-6736(83)91987-6. [DOI] [PubMed] [Google Scholar]
  24. Oswald E., Sugai M., Labigne A., Wu H. C., Fiorentini C., Boquet P., O'Brien A. D. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3814–3818. doi: 10.1073/pnas.91.9.3814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta. 1997 Oct 24;1333(2):C1–C6. doi: 10.1016/s0304-419x(97)00021-8. [DOI] [PubMed] [Google Scholar]
  26. Sands K. E., Bates D. W., Lanken P. N., Graman P. S., Hibberd P. L., Kahn K. L., Parsonnet J., Panzer R., Orav E. J., Snydman D. R. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997 Jul 16;278(3):234–240. [PubMed] [Google Scholar]
  27. Saxena S. K., O'Brien A. D., Ackerman E. J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989 Jan 5;264(1):596–601. [PubMed] [Google Scholar]
  28. Schlievert P. M. Searching for superantigens. Immunol Invest. 1997 Jan-Feb;26(1-2):283–290. doi: 10.3109/08820139709048934. [DOI] [PubMed] [Google Scholar]
  29. Schmidt G., Sehr P., Wilm M., Selzer J., Mann M., Aktories K. Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature. 1997 Jun 12;387(6634):725–729. doi: 10.1038/42735. [DOI] [PubMed] [Google Scholar]
  30. Song L., Hobaugh M. R., Shustak C., Cheley S., Bayley H., Gouaux J. E. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science. 1996 Dec 13;274(5294):1859–1866. doi: 10.1126/science.274.5294.1859. [DOI] [PubMed] [Google Scholar]
  31. Songer J. G. Bacterial phospholipases and their role in virulence. Trends Microbiol. 1997 Apr;5(4):156–161. doi: 10.1016/S0966-842X(97)01005-6. [DOI] [PubMed] [Google Scholar]
  32. Stein P. E., Boodhoo A., Tyrrell G. J., Brunton J. L., Read R. J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature. 1992 Feb 20;355(6362):748–750. doi: 10.1038/355748a0. [DOI] [PubMed] [Google Scholar]
  33. Taga S., Mangeney M., Tursz T., Wiels J. Differential regulation of glycosphingolipid biosynthesis in phenotypically distinct Burkitt's lymphoma cell lines. Int J Cancer. 1995 Apr 10;61(2):261–267. doi: 10.1002/ijc.2910610220. [DOI] [PubMed] [Google Scholar]
  34. Tesh V. L., O'Brien A. D. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Microbiol. 1991 Aug;5(8):1817–1822. doi: 10.1111/j.1365-2958.1991.tb00805.x. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES